Viatris Inc SEC filings VTRS
Viatris Inc has 542 filings in SEC EDGAR's recent list, going back to Oct 25, 2019. Its latest annual report, Form ARS, was filed on Apr 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 2, 2026 | — |
| DEF 14A | Proxy statement | Apr 2, 2026 | May 15, 2026 |
| DEFA14A | Additional proxy material | Oct 24, 2025 | — |
| DEF 14A | Proxy statement | Oct 24, 2025 | Dec 5, 2025 |
| DEFA14A | Additional proxy material | Oct 25, 2024 | — |
| DEF 14A | Proxy statement | Oct 25, 2024 | Dec 6, 2024 |
| DEFA14A | Additional proxy material | Nov 24, 2023 | — |
| DEFA14A | Additional proxy material | Nov 3, 2023 | — |
| DEF 14A | Proxy statement | Nov 3, 2023 | Dec 15, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 24, 2023 | Dec 15, 2023 |
| DEFA14A | Additional proxy material | Nov 14, 2022 | — |
| DEFA14A | Additional proxy material | Oct 28, 2022 | — |
| DEF 14A | Proxy statement | Oct 28, 2022 | Dec 9, 2022 |
| DEFA14A | Additional proxy material | Oct 29, 2021 | — |
| DEF 14A | Proxy statement | Oct 29, 2021 | Dec 10, 2021 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Canonsburg, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1792044
- Former names
- Upjohn Inc (until Nov 10, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.